Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30743 ↗At a glance
Journal article in Pediatric Blood & Cancer, 2024. Written by Vandana Batra and 10 co-authors. Institution: Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: 3-Iodobenzylguanidine, Neuroblastoma. Cited 4 times so far (Crossref); 19 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Background
Prior studies suggest that norepinephrine transporter (NET) and vesicular monoamine transporter 2 (VMAT2) mediate meta‐iodobenzylguanidine (MIBG) uptake and retention in neuroblastoma tumors. We evaluated the relationship between NET and VMAT2 tumor expression and clinical response to 131 I‐MIBG therapy in patients with neuroblastoma.
Methods
Immunohistochemistry (IHC) was used to evaluate NET and VMAT2 protein expression levels on archival tumor samples (obtained at diagnosis or relapse) from patients with relapsed or refractory neuroblastoma treated with 131 I‐MIBG. A composite protein expression H ‐score was determined by multiplying a semi‐quantitative intensity value (0–3+) by the percentage of tumor cells expressing the protein.
Results
Tumor samples and clinical data were available for 106 patients, of whom 28.3% had partial response (PR) or higher. NET H ‐score was not significantly associated with response (≥PR), though the percentage of tumor cells expressing NET was lower among responders (median 80% for ≥PR vs. 90% for
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, Children's Hospital Los Angeles and USC Keck School of Medicine, Los Angeles, California, USA.
- Department of Pediatrics, Cook Children's Hospital, Fort Worth, Texas, USA.
- Department of Pediatrics, Children's Hospital Los Angeles and USC Keck School of Medicine, Los Angeles, California, USA.
- Department of Pediatrics, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington, USA.
ORCID profiles: Ajami Gikandi, Araz Marachelian, John M Maris, Kieuhoa T Vo, Katherine K Matthay, Steven G DuBois
Funding
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Batra, V., Gikandi, A., Pawel, B., Martinez, D., Granger, M. M., Marachelian, A., Park, J. R., Maris, J. M., Vo, K. T., Matthay, K. K., & DuBois, S. G. (2024). Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30743
Vancouver
Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, et al. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30743
BibTeX
@article{Batra2024,
author = {Batra, Vandana and Gikandi, Ajami and Pawel, Bruce and Martinez, Daniel and Granger, M Meaghan and Marachelian, Araz and Park, Julie R and Maris, John M and Vo, Kieuhoa T and Matthay, Katherine K and DuBois, Steven G},
title = {Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30743}
}
EUVIMED